Loading organizations...
§ Private Profile · Bethesda, MD, USA
Biotech startup developing pancreatic beta-cell modulators for type 1 and type 2 diabetes, focused on preclinical beta-cell regeneration.
Based in Marseille with research labs in Nice, DiogenX is a biotechnology startup that develops pancreatic beta-cell modulators as regenerative treatments for type 1 and type 2 diabetes. The enterprise focuses on advancing experimental therapies based on extensive research into beta-cell regeneration from early preclinical stages to target these chronic conditions. Founded in December 2019 by Chief Executive Officer Benjamin Charles alongside Patrick Collombat and Jean-Pascal Tranié, the company operates through a venture capital business model. To support its pipeline, the firm has raised a total of 35,100,000 dollars across an initial 4,500,000 euro seed round and a subsequent 27,500,000 euro Series A financing package. This financial backing comes from a syndicate of notable life science investors including Advent France Biotechnology, the Boehringer Ingelheim Venture Fund, the JDRF T1D Fund, and the Roche Venture Fund.
DioGenix has raised $4.7M across 2 funding rounds.
DioGenix has raised $4.7M in total across 2 funding rounds.
DioGenix has raised $4.7M across 2 funding rounds. Most recently, it raised $3.2M Other Equity in December 2013.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 5, 2013 | $3.2M Venture Round | Nerveda | — | Announced |
| Dec 19, 2012 | $1.5M Series B | CAM Gallagher | — | Announced |
DioGenix has raised $4.7M in total across 2 funding rounds.
DioGenix's investors include Nerveda, Cam Gallagher.